Pharmacological management of nonalcoholic fatty liver disease
Diana Barb, Paola Portillo-Sánchez, Kenneth J. Cusi · Metabolism · 2016
Nonalcoholic fatty liver disease (NAFLD) affects one-third of the population and two-thirds of patients with obesity or type 2 diabetes (T2DM). Its more aggressive form is known as nonalcoholic steatohepatitis (NASH) and is characterized by hepatocyte necrosis, inflammation and often fibrosis. The presence of fibrosis indicates a more aggressive course and may lead to cirrhosis. Premature mortality in NASH is related to both hepatic (cirrhosis and hepatocellular carcinoma) and extra-hepatic complications, largely cardiovascular disease (CVD). Many therapeutic agents have been tested, but still none approved specifically for NASH. Treatment of NAFLD includes aggressive management of diabetes and cardiovascular risk factors, although the role of controlling hyperglycemia per se in patients with T2DM and NASH remains unknown. Agents tested with some success in non-diabetic patients with NASH include pioglitazone, liraglutide, vitamin E and to a lesser degree, pentoxiphylline. In patients with T2DM and NASH only pioglitazone has shown to significantly improve liver histology, with only a handful of patients with diabetes having been studied with other modalities. This review focuses on available agents for NASH to assist clinicians in the management of these complex patients. Many novel compounds are being studied and will likely make combination therapy for NASH a reality in the future.
Cited by 114 works. doi:10.1016/j.metabol.2016.04.004 Open-access PDF
Authors
References
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- The NAFLD fibrosis score
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management